Neuro-Immune-Endocrine Integration Failure (NIEIF)

Neuro-Immune-Endocrine Integration Failure (NIEIF) | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Systematic Review Neuro-Immune-Endocrine Integration Failure (NIEIF) Dr.Purusharth Kumar Sharma, Dr. Neha Laskar This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8202736/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Some patients present with overlapping but unexplained symptoms pelvic pain, fatigue, urticaria, palpitations, gastrointestinal distress, neuropathic pain, and mood dysregulation. These symptoms, traditionally diagnosed under separate labels (endometriosis, MCAS, IBS, dysautonomia, chronic fatigue),We share a unifying pathophysiological signature disruption of neuro-immune-endocrine coordination. We define this as Neuro-Immune-Endocrine Integration Failure (NIEIF) , clinically observed as the Purusharth–Neha Multisystem Stress-Responsive Dysregulation Syndrome (PN-MSRDS) . NIEIF represents a systems-level breakdown in communication between mast cells, cytokine networks, neurogenic circuits, and hormonal regulators. This article expands the mechanistic model, clinical spectrum, diagnostic algorithms, and therapeutic rationale for this newly characterized condition. 1. Introduction Patients with chronic multisystem symptoms often move between gastroenterology, gynecology, dermatology, neurology, psychiatry, and cardiology without receiving a unifying diagnosis. Conditions such as: Mast-Cell Activation Syndrome (MCAS), Endometriosis, Irritable Bowel Syndrome (IBS), Postural Orthostatic Tachycardia Syndrome (POTS), Chronic Spontaneous Urticaria, Unexplained pelvic pain, Chronic fatigue and sleep dysregulation Neuropsychiatric symptoms (anxiety, irritability)are frequently overlapping but treated in silos. Clinical patterns strongly suggest a shared systemic dysfunction involving: Mast-cell hyperresponsiveness , Cytokine amplification especially IL-6/STAT3 , Hormonal sensitivity especially estrogen-dependent loops , Neurogenic cross-talk and autonomic instability NIEIF provides a cohesive framework to integrate these domains into one systems biology disorder rather than many organ-based disorders . 2. Pathophysiology of NIEIF NIEIF arises when the neuro–immune–endocrine network loses synchrony , transforming normal stress responses into self-amplifying pathological loops . 2.1 Mast-Cell Overactivation as the Primary Node Mast cells in skin, gut, uterus, bladder, and vasculature respond to: Neuropeptides (Substance P, CGRP), Estrogen and progesterone fluctuations, Stress hormones (CRH), Environmental triggers (pollutants, microplastics, EDCs) Dysregulated mast cells release: Histamine, Tryptase, IL-6, TNF-α, Prostaglandins, leukotrienes, Nerve-growth factors (NGF) This results in: Pain sensitization, Vascular instability (palpitations, POTS), Skin and gut inflammation, Hormonal reactivity MRGPRX2-mediated activation explains non-allergic flares , drug intolerance, and stress-evoked episodes. 2.2 Cytokine Amplification via IL-6 → JAK → STAT3 After activation, mast cells stimulate stromal and immune cells to produce excess IL-6 , which triggers STAT3 nuclear translocation. Consequences: Sustained inflammation even without triggers, Increased angiogenesis, tissue edema, Persistence of endometriosis lesions, Central neuroinflammation and sickness behavior, Autonomic imbalance and fatigue, STAT3 is considered the “master amplifier” of NIEIF. 2.2 Neurogenic Feedback: Brain–Body Loop Disintegration Peripheral inflammation signals the brain via: Vagal afferents, Circulating cytokines, Dural lymphatics (glymphatic pathway) Central effects: Microglial activation, Altered limbic neurotransmission, HPA-axis instability, Sympathetic overdrive This causes: Palpitations, tachycardia, POTS, Anxiety, irritability, Sleep disturbances, Sensory hypersensitivity, Sympathetic neuropeptides then re-trigger mast cells , closing the loop. 2.3 Hormonal Node: Estrogen as a Pathology Multiplier Estrogen surges: Increase mast-cell granule content, Up-regulate IL-6 transcription, Reduce regulatory T-cell activity Clinical implications: Premenstrual worsening, Flare-ups during ovulation or luteal phase, High prevalence in women of reproductive age, Exacerbation of pain, urticaria, GI symptoms 2.4 Epigenetic Reinforcement Chronic exposure to stress and inflammation alters: DNA methylation ,Histone acetylation ,Mast-cell transcriptional set-points ,Microglial reactivity thresholds This “locks” the system into a high-gain, hyper-reactive state . 2.6 Systems Biology Integration Three interlinked nodes define NIEIF: M node : Mast-cell hyperactivation C node : Cytokine amplification (IL-6/STAT3) H node : Hormonal sensitivity Their interactions produce emergent phenomena: Chronic pain syndromes, Dysautonomia ,Cutaneous flares, Neuropsychiatric disturbances-like bowel dysfunction NIEIF is thus a network disease , not an individual-organ disease. 3. Clinical Phenotype NIEIF produces a recognizable but polymorphic syndrome , with symptoms across organ systems. Dermatologic manifestations, Urticaria (chronic or inducible), Facial flushing, Dermographism, Burning, stinging episodes, non-allergic drug reactions Gynecologic/Pelvic manifestations, Endometriosis -like pelvic pain, Dyspareunia, Cyclic symptom flares, Infertility in some cases Autonomic manifestations ,POTS ,Tachycardia episodes ,Heat intolerance ,Temperature regulation disturbances Gastrointestinal manifestations ,IBS-D/IBS-M symptoms ,Bloating, early satiety ,Food intolerances ,Cyclic nausea Neuropsychiatric symptoms ,Brain fog ,Irritability/anxiety ,Sleep disruption ,Stress sensitivity Systemic/Constitutional features ,Chronic fatigue ,Myalgias and widespread pain .Exertional intolerance ,Episodic hypotension or dizziness 4. Diagnostic Framework 4.1 Clinical Red Flags Suggesting NIEIF Multisystem symptoms without clear organic basis Flares linked to stress or hormonal changes History of drug/food sensitivities Combination of dermatologic + autonomic + GI + pelvic symptoms 4.2 Laboratory Evaluation No single biomarker yet; supportive markers include: Serum tryptase (normal in most) Plasma histamine Urinary methylhistamine Serum IL-6, TNF-α CRP, ESR ANA/autoimmune profiles 4.3 Autonomic Testing Tilt-table test for POTS Heart-rate variability 4.4 Imaging / Organ-Specific Tests Used mainly to rule out other conditions. 4.5 Phenotype-Based Subclassification Cutaneous-dominant Pelvic-pain dominant GI-dominant Autonomic-dominant Neuropsychiatric-dominant 5. Management Implications 5.1 Treatment Principles Multi-system involvement requires multi-node stabilization ,Targeting mast cells alone is insufficient ,Cytokine modulation + hormonal regulation + autonomic rehabilitation are essential 5.2 Established Therapeutic Pillars 1. Mast-cell stabilization H1 + H2 blockers ,Ketotifen ,Cromolyn 2. Cytokine modulation , Anti-inflammatory nutraceuticals ,Low-dose naltrexone (LDN) ,IL-6-lowering lifestyle interventions 3. Hormonal rhythm stabilization , avoiding extreme estrogen fluctuations, Gynecologic evaluation when indicated 4. Autonomic rehabilitation ,Hydration, salt loading ,Compression garments ,Graded exercise therapy 5. Neuroimmune stabilization ,Sleep normalization ,Stress-modulation strategies ,Gut–brain axis interventions 6. Conclusion NIEIF represents a unifying pathophysiological model for widespread, multi-organ symptoms traditionally diagnosed as separate disorders. By recognizing the interconnected loops of mast-cell hyperreactivity, cytokine amplification, hormonal modulation, and neurogenic feedback, clinicians gain a systems-level understanding of chronic inflammatory and stress-responsive diseases. NIEIF as a framework can improve diagnostic clarity, therapeutic coherence, and patient outcomes. Declarations Author Contribution Author ContributionsDr. Purusharth Kumar SharmaConceptualization: Developed the central hypothesis of Neuro-Immune-Endocrine Integration Failure (NIEIF) and its clinical framework.Methodology & Investigation: Conducted the literature integration across immunology, neurology, endocrinology, and systems biology.Writing – Original Draft: Prepared the primary manuscript, figures, and mechanistic descriptions.Data Curation & Analysis: Synthesized evidence from >200 peer-reviewed studies and organized mechanistic pathways.Visualization: Designed conceptual models, flow diagrams, and clinical phenotype charts.Project Administration: Oversaw manuscript structure, ensured scientific consistency, and coordinated final revisions.Final Approval: Reviewed and approved the completed manuscript.Dr. Neha LaskarWriting – Review & Editing: Refined the manuscript for clarity, coherence, and clinical relevance; contributed critical revisions.Validation: Assessed the accuracy of immunological and hormonal pathway interpretations.Supervision: Provided expert oversight on clinical applicability, patient phenotype integration, and diagnostic framework development.Final Approval: Reviewed and approved the final manuscript.Both authors agree to be accountable for all aspects of the work, ensuring accuracy and integrity. References Afrin LB, Weinstock LB, Molderings GJ. Diagnosis of mast cell activation syndrome: a global consensus-2. J Allergy Clin Immunol Pract. 2020;8(2):498–e5061. Weiler CR. Mast cell activation syndrome: tools for diagnosis and differential diagnosis. J Allergy Clin Immunol Pract. 2020;8(2):512–20. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for urticaria. Allergy. 2018;73(7):1393–414. Castells M. Mast cells and Mas-related G protein-coupled receptor X2 (MRGPRX2): clinical implications. J Allergy Clin Immunol. 2024; (review). Toscano A, et al. MRGPRX2 in human mast cell biology and disease. Front Immunol. 2023;14:1026304. Bawazir M, et al. Inhibition of MRGPRX2 but not FcεRI-mediated mast cell activation: implications for hypersensitivity. Front Immunol. 2022;13:1033794. McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor critical for pseudo-allergic drug reactions. Nature. 2015;519:237–41. Theoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822:21–33. Roy S et al. New insights into mast cells in health and disease. J Allergy Clin Immunol. 2021; (review). Kitamura H, Kawai T, Akira S. IL-6/STAT3 signaling as a target in inflammation. Int J Cancer. 2017;140(12):2474–83. Garbers C, Heink S, Korn T, Rose-John S. The IL-6/gp130/STAT3 axis: advances and therapeutic perspectives. Trends Pharmacol Sci. 2015;36(10):744–58. Cronin JG, Maybin JA, Malik S, Critchley HOD. IL-6/STAT3 signalling in endometrial cells: relevance to endometriosis. Mucosal Immunol. 2016;9:1043–55. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Principles of IL-6-type cytokine signalling. Biochem J. 2003;374(Pt 1):1–20. Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. 2018;10(2):a028415. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness behavior. Nat Rev Neurosci. 2008;9(1):46–56. Johnson RW, et al. Peripheral inflammation induces CNS cytokine production. Brain Behav Immun. 2005;19:358–71. Kynast KL, Russe OQ, Geisslinger G, et al. Immune contributions to chronic pain. Nat Rev Neurosci. 2020;21:145–62. Mayer EA. Gut feelings: the emerging biology of gut–brain communication. Nat Rev Neurosci. 2011;12(8):453–66. Margolis KG, Cryan JF, Mayer EA. The microbiota–gut–brain axis. Gastroenterology. 2021;160(5):1486–501. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut–brain axis: interactions between microbiota and nervous system. Ann Gastroenterol. 2015;28:203–9. Osadchiy V, Martin CR, Mayer EA. GI–brain axis and clinical implications. Clin Gastroenterol Hepatol. 2019;17(2):322–32. Ransohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777–83. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;10:217–24. Miller AH, Raison CL. Inflammation in depression. Nat Rev Immunol. 2016;16(1):22–34. Hassamal S, et al. Chronic stress, neuroinflammation, and depression: emerging mechanisms. Front Psychiatry. 2023;14:1130989. Hiles SA, Baker AL, de Malmanche T, Attia J. Inflammatory biomarkers in depression. BJPsych Open. 2024;10(5):e165. Freeman R, et al. Consensus on definition & classification of POTS. Clin Auton Res. 2018;28(3):355–65. Raj SR. Pathophysiology of postural tachycardia syndrome. Auton Neurosci. 2013;172:1–4. Moya A, et al. ESC guidelines for diagnosis & management of syncope. Eur Heart J. 2009;30:2631–67. Stewart JM. Mechanisms of sympathetic activation in POTS. Am J Physiol Heart Circ Physiol. 2012;303:H1752–63. Hsu AL, Khachikyan I, Stratton P. Inflammation and endometriosis. Semin Reprod Med. 2012;30(1):26–34. Zondervan KT, Becker CM, Missmer SA, Endometriosis. N Engl J Med. 2020;382:1244–56. Giudice LC, Kao LC, Endometriosis. Lancet. 2004;364:1789–99. Seneviratne U, et al. Sex hormones and mast cell modulation. Reprod Biomed Online. 2013;26:617–26. Kudryavtseva AV, et al. Estrogen-dependent regulation of mast cells. J Endocrinol. 2020;244:R1–15. Hitti E, et al. Estrogen & immune function—autoimmunity link. Semin Reprod Med. 2010;28:326–33. Kalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008;9(11):1215–22. Galli SJ, Tsai M, Piliponsky AM. Development of allergic inflammation. Nature. 2008;454:445–54. Yarovinsky TO, et al. Substance P–mast cell interactions. J Neuroimmunol. 2013;266:20–6. Theoharides TC, Kavaliotis J, Panagiotou M, et al. Mast cells in neuroinflammatory disorders. Int Rev Neurobiol. 2016;131:25–44. Rittner HL, Brack A, et al. Mast cell–nociceptor interactions in pain. Curr Opin Neurobiol. 2013;23:560–7. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med. 2010;16:1248–57. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8202736","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Systematic Review","associatedPublications":[],"authors":[{"id":550539634,"identity":"3a315b12-e07d-491f-9f66-0670d9c620fc","order_by":0,"name":"Dr.Purusharth Kumar Sharma","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA4klEQVRIiWNgGAWjYPCCA0DMw/gARPIRr4WNh9kApIWNFC1sEiAmQS3ys3vMPvP8uSNvPr/3WOXXHDsZNgbmh49u4NFicOeM8WzetmeGc47xpd2W3ZYMdBibsXEOPi0SOcbMvA2HGWew8ZjdltzGDNTCwyaNT4v8DKAWnj+H7UFaiiW31RPWwnADpIXtcCJIC+PHbYcJazG4c6yYcW7b4eQZbDnG0ozbjvOwMRPwi/zs5s0Mb/4ctp3BfMbw489t1fb87M0PH+N1mAQSm5kHTOJTjq6F8Qch1aNgFIyCUTAiAQCBcEFRe/p3DAAAAABJRU5ErkJggg==","orcid":"","institution":"Rajasthan Dental College and Hospital","correspondingAuthor":true,"prefix":"Dr.","firstName":"Purusharth","middleName":"Kumar","lastName":"Sharma","suffix":""},{"id":550539636,"identity":"3b149563-6bf2-4210-82ee-8ae344f9790a","order_by":1,"name":"Dr. Neha Laskar","email":"","orcid":"","institution":"Rajasthan Dental College and Hospital","correspondingAuthor":false,"prefix":"Dr.","firstName":"Neha","middleName":"","lastName":"Laskar","suffix":""}],"badges":[],"createdAt":"2025-11-25 11:38:19","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8202736/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8202736/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":96789183,"identity":"76cdcb1d-065b-49ef-af6c-c99d4338cce9","added_by":"auto","created_at":"2025-11-26 06:42:43","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":29439,"visible":true,"origin":"","legend":"","description":"","filename":"PN.docx","url":"https://assets-eu.researchsquare.com/files/rs-8202736/v1/1c50f2ab2c6a39f9dc965400.docx"},{"id":96789180,"identity":"e889acc1-b8b1-4740-9b47-d3750dff6dce","added_by":"auto","created_at":"2025-11-26 06:42:43","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":4644,"visible":true,"origin":"","legend":"","description":"","filename":"a05a9d3a0d8d4987aff4e9950193ef03.json","url":"https://assets-eu.researchsquare.com/files/rs-8202736/v1/634cb6de9f385962d12f6ceb.json"},{"id":96789181,"identity":"d76804aa-48c7-4318-b961-f5ee0243ad27","added_by":"auto","created_at":"2025-11-26 06:42:43","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":58516,"visible":true,"origin":"","legend":"","description":"","filename":"a05a9d3a0d8d4987aff4e9950193ef031enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8202736/v1/549555823b088c2db0472d43.xml"},{"id":96789182,"identity":"6a482b9e-9400-40ee-b9b7-a41eb8a0a37d","added_by":"auto","created_at":"2025-11-26 06:42:43","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":51258,"visible":true,"origin":"","legend":"","description":"","filename":"a05a9d3a0d8d4987aff4e9950193ef031structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8202736/v1/971ecd5799865bc9f1c54def.xml"},{"id":96789184,"identity":"a8cb750e-6092-4abc-a456-45bceb49aa1e","added_by":"auto","created_at":"2025-11-26 06:42:43","extension":"html","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":68424,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8202736/v1/5f36755e715db3c0fae3fbd8.html"},{"id":97863110,"identity":"d5d77193-2ecc-4e58-894d-f1af48e4d4da","added_by":"auto","created_at":"2025-12-10 09:10:16","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":958687,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8202736/v1/a5abb15a-84c2-4243-827c-65ef87147173.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Neuro-Immune-Endocrine Integration Failure (NIEIF)","fulltext":[{"header":"1. Introduction","content":"\u003cp\u003ePatients with chronic multisystem symptoms often move between gastroenterology, gynecology, dermatology, neurology, psychiatry, and cardiology without receiving a unifying diagnosis. Conditions such as: Mast-Cell Activation Syndrome (MCAS), Endometriosis, Irritable Bowel Syndrome (IBS), Postural Orthostatic Tachycardia Syndrome (POTS), Chronic Spontaneous Urticaria, Unexplained pelvic pain, Chronic fatigue and sleep dysregulation Neuropsychiatric symptoms (anxiety, irritability)are frequently overlapping but treated in silos.\u003c/p\u003e\u003cp\u003eClinical patterns strongly suggest a \u003cb\u003eshared systemic dysfunction\u003c/b\u003e involving: \u003cb\u003eMast-cell hyperresponsiveness\u003c/b\u003e, \u003cb\u003eCytokine amplification especially IL-6/STAT3\u003c/b\u003e, Hormonal \u003cb\u003esensitivity especially estrogen-dependent loops\u003c/b\u003e, Neurogenic \u003cb\u003ecross-talk and autonomic instability\u003c/b\u003e\u003c/p\u003e\u003cp\u003eNIEIF provides a cohesive framework to integrate these domains into \u003cb\u003eone systems biology disorder rather than many organ-based disorders\u003c/b\u003e.\u003c/p\u003e"},{"header":"2. Pathophysiology of NIEIF","content":"\u003cp\u003eNIEIF arises when the \u003cb\u003eneuro–immune–endocrine network loses synchrony\u003c/b\u003e, transforming normal stress responses into \u003cb\u003eself-amplifying pathological loops\u003c/b\u003e.\u003c/p\u003e\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e\u003ch2\u003e2.1 Mast-Cell Overactivation as the Primary Node\u003c/h2\u003e\u003cp\u003eMast cells in skin, gut, uterus, bladder, and vasculature respond to: Neuropeptides (Substance P, CGRP), Estrogen and progesterone fluctuations, Stress hormones (CRH), Environmental triggers (pollutants, microplastics, EDCs)\u003c/p\u003e\u003cp\u003eDysregulated mast cells release: Histamine, Tryptase, IL-6, TNF-α, Prostaglandins, leukotrienes, Nerve-growth factors (NGF)\u003c/p\u003e\u003cp\u003eThis results in: Pain sensitization, Vascular instability (palpitations, POTS), Skin and gut inflammation, Hormonal reactivity\u003c/p\u003e\u003cp\u003eMRGPRX2-mediated activation explains \u003cb\u003enon-allergic flares\u003c/b\u003e, drug intolerance, and stress-evoked episodes.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec4\" class=\"Section2\"\u003e\u003ch2\u003e2.2 Cytokine Amplification via IL-6 → JAK → STAT3\u003c/h2\u003e\u003cp\u003eAfter activation, mast cells stimulate stromal and immune cells to produce \u003cb\u003eexcess IL-6\u003c/b\u003e, which triggers STAT3 nuclear translocation.\u003c/p\u003e\u003cp\u003eConsequences: Sustained inflammation even without triggers, Increased angiogenesis, tissue edema, Persistence of endometriosis lesions, Central neuroinflammation and sickness behavior, Autonomic imbalance and fatigue, STAT3 is considered the \u003cb\u003e“master amplifier”\u003c/b\u003e of NIEIF.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec5\" class=\"Section2\"\u003e\u003ch2\u003e2.2 Neurogenic Feedback: Brain–Body Loop Disintegration\u003c/h2\u003e\u003cp\u003ePeripheral inflammation signals the brain via: Vagal afferents, Circulating cytokines, Dural lymphatics (glymphatic pathway)\u003c/p\u003e\u003cp\u003eCentral effects: Microglial activation, Altered limbic neurotransmission, HPA-axis instability, Sympathetic overdrive\u003c/p\u003e\u003cp\u003eThis causes: Palpitations, tachycardia, POTS, Anxiety, irritability, Sleep disturbances, Sensory hypersensitivity, Sympathetic neuropeptides then \u003cb\u003ere-trigger mast cells\u003c/b\u003e, closing the loop.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec6\" class=\"Section2\"\u003e\u003ch2\u003e2.3 Hormonal Node: Estrogen as a Pathology Multiplier\u003c/h2\u003e\u003cp\u003eEstrogen surges: Increase mast-cell granule content, Up-regulate IL-6 transcription, Reduce regulatory T-cell activity\u003c/p\u003e\u003cp\u003eClinical implications: Premenstrual worsening, Flare-ups during ovulation or luteal phase, High prevalence in women of reproductive age, Exacerbation of pain, urticaria, GI symptoms\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec7\" class=\"Section2\"\u003e\u003ch2\u003e2.4 Epigenetic Reinforcement\u003c/h2\u003e\u003cp\u003eChronic exposure to stress and inflammation alters: DNA methylation ,Histone acetylation ,Mast-cell transcriptional set-points ,Microglial reactivity thresholds\u003c/p\u003e\u003cp\u003eThis “locks” the system into a \u003cb\u003ehigh-gain, hyper-reactive state\u003c/b\u003e.\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec8\" class=\"Section2\"\u003e\u003ch2\u003e2.6 Systems Biology Integration\u003c/h2\u003e\u003cp\u003eThree interlinked nodes define NIEIF:\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eM node\u003c/b\u003e: Mast-cell hyperactivation\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eC node\u003c/b\u003e: Cytokine amplification (IL-6/STAT3)\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eH node\u003c/b\u003e: Hormonal sensitivity\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003eTheir interactions produce emergent phenomena: Chronic pain syndromes, Dysautonomia ,Cutaneous flares, Neuropsychiatric disturbances-like bowel dysfunction\u003c/p\u003e\u003cp\u003eNIEIF is thus a \u003cb\u003enetwork disease\u003c/b\u003e, not an individual-organ disease.\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003cp\u003e\u003c/p\u003e\u003c/div\u003e"},{"header":"3. Clinical Phenotype","content":"\u003cul\u003e\u003cli\u003e\u003cp\u003eNIEIF produces a \u003cb\u003erecognizable but polymorphic syndrome\u003c/b\u003e, with symptoms across organ systems.\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eDermatologic manifestations, Urticaria\u003c/b\u003e (chronic or inducible), Facial flushing, Dermographism, Burning, stinging episodes, non-allergic drug reactions\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eGynecologic/Pelvic manifestations, Endometriosis\u003c/b\u003e-like pelvic pain, Dyspareunia, Cyclic symptom flares, Infertility in some cases\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eAutonomic manifestations\u003c/b\u003e ,POTS ,Tachycardia episodes ,Heat intolerance ,Temperature regulation disturbances\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eGastrointestinal manifestations\u003c/b\u003e ,IBS-D/IBS-M symptoms ,Bloating, early satiety ,Food intolerances ,Cyclic nausea\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eNeuropsychiatric symptoms\u003c/b\u003e ,Brain fog ,Irritability/anxiety ,Sleep disruption ,Stress sensitivity\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eSystemic/Constitutional features\u003c/b\u003e ,Chronic fatigue ,Myalgias and widespread pain .Exertional intolerance ,Episodic hypotension or dizziness\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e"},{"header":"4. Diagnostic Framework","content":"\u003cp\u003e\u003cb\u003e4.1 Clinical Red Flags Suggesting NIEIF\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003eMultisystem symptoms without clear organic basis\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eFlares linked to stress or hormonal changes\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eHistory of drug/food sensitivities\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eCombination of dermatologic\u0026thinsp;+\u0026thinsp;autonomic\u0026thinsp;+\u0026thinsp;GI\u0026thinsp;+\u0026thinsp;pelvic symptoms\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e\u003ch2\u003e4.2 Laboratory Evaluation\u003c/h2\u003e\u003cp\u003eNo single biomarker yet; supportive markers include:\u003c/p\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003eSerum tryptase (normal in most)\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003ePlasma histamine\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eUrinary methylhistamine\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eSerum IL-6, TNF-α\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eCRP, ESR\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eANA/autoimmune profiles\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003e4.3 Autonomic Testing\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003eTilt-table test for POTS\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003eHeart-rate variability\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003c/div\u003e\u003cdiv id=\"Sec11\" class=\"Section2\"\u003e\u003ch2\u003e4.4 Imaging / Organ-Specific Tests\u003c/h2\u003e\u003cp\u003eUsed mainly to rule out other conditions.\u003c/p\u003e\u003cp\u003e\u003cb\u003e4.5 Phenotype-Based Subclassification\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cul\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eCutaneous-dominant\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003ePelvic-pain dominant\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eGI-dominant\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eAutonomic-dominant\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003cli\u003e\u003cp\u003e\u003cb\u003eNeuropsychiatric-dominant\u003c/b\u003e\u003c/p\u003e\u003c/li\u003e\u003c/ul\u003e\u003c/p\u003e\u003c/div\u003e"},{"header":"5. Management Implications","content":"\u003cp\u003e\u003cstrong\u003e5.1\u0026nbsp;Treatment Principles\u0026nbsp;\u003c/strong\u003eMulti-system involvement requires \u003cstrong\u003emulti-node stabilization\u003c/strong\u003e ,Targeting mast cells alone is insufficient ,Cytokine modulation + hormonal regulation + autonomic rehabilitation are essential\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e5.2\u0026nbsp;Established Therapeutic Pillars\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e1. \u003cstrong\u003eMast-cell stabilization\u003c/strong\u003e H1 + H2 blockers ,Ketotifen ,Cromolyn\u003c/p\u003e\n\u003cp\u003e2. \u003cstrong\u003eCytokine modulation\u003c/strong\u003e, Anti-inflammatory nutraceuticals ,Low-dose naltrexone (LDN) ,IL-6-lowering lifestyle interventions\u003c/p\u003e\n\u003cp\u003e3. \u003cstrong\u003eHormonal rhythm stabilization\u003c/strong\u003e, avoiding extreme estrogen fluctuations, Gynecologic evaluation when indicated\u003c/p\u003e\n\u003cp\u003e4. \u003cstrong\u003eAutonomic rehabilitation\u003c/strong\u003e ,Hydration, salt loading ,Compression garments ,Graded exercise therapy\u003c/p\u003e\n\u003cp\u003e5. \u003cstrong\u003eNeuroimmune stabilization\u003c/strong\u003e ,Sleep normalization ,Stress-modulation strategies ,Gut\u0026ndash;brain axis interventions\u003c/p\u003e"},{"header":"6. Conclusion","content":"\u003cp\u003eNIEIF represents a \u003cb\u003eunifying pathophysiological model\u003c/b\u003e for widespread, multi-organ symptoms traditionally diagnosed as separate disorders. By recognizing the interconnected loops of mast-cell hyperreactivity, cytokine amplification, hormonal modulation, and neurogenic feedback, clinicians gain a systems-level understanding of chronic inflammatory and stress-responsive diseases.\u003c/p\u003e\u003cp\u003eNIEIF as a framework can improve diagnostic clarity, therapeutic coherence, and patient outcomes.\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAuthor Contribution\u003c/h2\u003e\u003cp\u003eAuthor ContributionsDr. Purusharth Kumar SharmaConceptualization: Developed the central hypothesis of Neuro-Immune-Endocrine Integration Failure (NIEIF) and its clinical framework.Methodology \u0026amp; Investigation: Conducted the literature integration across immunology, neurology, endocrinology, and systems biology.Writing \u0026ndash; Original Draft: Prepared the primary manuscript, figures, and mechanistic descriptions.Data Curation \u0026amp; Analysis: Synthesized evidence from \u0026gt;200 peer-reviewed studies and organized mechanistic pathways.Visualization: Designed conceptual models, flow diagrams, and clinical phenotype charts.Project Administration: Oversaw manuscript structure, ensured scientific consistency, and coordinated final revisions.Final Approval: Reviewed and approved the completed manuscript.Dr. Neha LaskarWriting \u0026ndash; Review \u0026amp; Editing: Refined the manuscript for clarity, coherence, and clinical relevance; contributed critical revisions.Validation: Assessed the accuracy of immunological and hormonal pathway interpretations.Supervision: Provided expert oversight on clinical applicability, patient phenotype integration, and diagnostic framework development.Final Approval: Reviewed and approved the final manuscript.Both authors agree to be accountable for all aspects of the work, ensuring accuracy and integrity.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eAfrin LB, Weinstock LB, Molderings GJ. Diagnosis of mast cell activation syndrome: a global consensus-2. J Allergy Clin Immunol Pract. 2020;8(2):498\u0026ndash;e5061.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWeiler CR. Mast cell activation syndrome: tools for diagnosis and differential diagnosis. J Allergy Clin Immunol Pract. 2020;8(2):512\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZuberbier T, Aberer W, Asero R, et al. The EAACI/GA\u0026sup2;LEN/EDF/WAO guideline for urticaria. Allergy. 2018;73(7):1393\u0026ndash;414.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCastells M. Mast cells and Mas-related G protein-coupled receptor X2 (MRGPRX2): clinical implications. J Allergy Clin Immunol. 2024; (review).\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eToscano A, et al. MRGPRX2 in human mast cell biology and disease. Front Immunol. 2023;14:1026304.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBawazir M, et al. Inhibition of MRGPRX2 but not FcεRI-mediated mast cell activation: implications for hypersensitivity. Front Immunol. 2022;13:1033794.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMcNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor critical for pseudo-allergic drug reactions. Nature. 2015;519:237\u0026ndash;41.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTheoharides TC, Alysandratos KD, Angelidou A, et al. Mast cells and inflammation. Biochim Biophys Acta. 2012;1822:21\u0026ndash;33.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRoy S et al. New insights into mast cells in health and disease. J Allergy Clin Immunol. 2021; (review).\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKitamura H, Kawai T, Akira S. IL-6/STAT3 signaling as a target in inflammation. Int J Cancer. 2017;140(12):2474\u0026ndash;83.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGarbers C, Heink S, Korn T, Rose-John S. The IL-6/gp130/STAT3 axis: advances and therapeutic perspectives. Trends Pharmacol Sci. 2015;36(10):744\u0026ndash;58.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCronin JG, Maybin JA, Malik S, Critchley HOD. IL-6/STAT3 signalling in endometrial cells: relevance to endometriosis. Mucosal Immunol. 2016;9:1043\u0026ndash;55.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHeinrich PC, Behrmann I, M\u0026uuml;ller-Newen G, Schaper F, Graeve L. Principles of IL-6-type cytokine signalling. Biochem J. 2003;374(Pt 1):1\u0026ndash;20.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. 2018;10(2):a028415.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eDantzer R, O\u0026rsquo;Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness behavior. Nat Rev Neurosci. 2008;9(1):46\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJohnson RW, et al. Peripheral inflammation induces CNS cytokine production. Brain Behav Immun. 2005;19:358\u0026ndash;71.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKynast KL, Russe OQ, Geisslinger G, et al. Immune contributions to chronic pain. Nat Rev Neurosci. 2020;21:145\u0026ndash;62.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMayer EA. Gut feelings: the emerging biology of gut\u0026ndash;brain communication. Nat Rev Neurosci. 2011;12(8):453\u0026ndash;66.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMargolis KG, Cryan JF, Mayer EA. The microbiota\u0026ndash;gut\u0026ndash;brain axis. Gastroenterology. 2021;160(5):1486\u0026ndash;501.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCarabotti M, Scirocco A, Maselli MA, Severi C. The gut\u0026ndash;brain axis: interactions between microbiota and nervous system. Ann Gastroenterol. 2015;28:203\u0026ndash;9.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eOsadchiy V, Martin CR, Mayer EA. GI\u0026ndash;brain axis and clinical implications. Clin Gastroenterol Hepatol. 2019;17(2):322\u0026ndash;32.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRansohoff RM. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777\u0026ndash;83.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePerry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol. 2014;10:217\u0026ndash;24.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMiller AH, Raison CL. Inflammation in depression. Nat Rev Immunol. 2016;16(1):22\u0026ndash;34.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHassamal S, et al. Chronic stress, neuroinflammation, and depression: emerging mechanisms. Front Psychiatry. 2023;14:1130989.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHiles SA, Baker AL, de Malmanche T, Attia J. Inflammatory biomarkers in depression. BJPsych Open. 2024;10(5):e165.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eFreeman R, et al. Consensus on definition \u0026amp; classification of POTS. Clin Auton Res. 2018;28(3):355\u0026ndash;65.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRaj SR. Pathophysiology of postural tachycardia syndrome. Auton Neurosci. 2013;172:1\u0026ndash;4.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMoya A, et al. ESC guidelines for diagnosis \u0026amp; management of syncope. Eur Heart J. 2009;30:2631\u0026ndash;67.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eStewart JM. Mechanisms of sympathetic activation in POTS. Am J Physiol Heart Circ Physiol. 2012;303:H1752\u0026ndash;63.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHsu AL, Khachikyan I, Stratton P. Inflammation and endometriosis. Semin Reprod Med. 2012;30(1):26\u0026ndash;34.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eZondervan KT, Becker CM, Missmer SA, Endometriosis. N Engl J Med. 2020;382:1244\u0026ndash;56.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGiudice LC, Kao LC, Endometriosis. Lancet. 2004;364:1789\u0026ndash;99.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSeneviratne U, et al. Sex hormones and mast cell modulation. Reprod Biomed Online. 2013;26:617\u0026ndash;26.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKudryavtseva AV, et al. Estrogen-dependent regulation of mast cells. J Endocrinol. 2020;244:R1\u0026ndash;15.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHitti E, et al. Estrogen \u0026amp; immune function\u0026mdash;autoimmunity link. Semin Reprod Med. 2010;28:326\u0026ndash;33.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKalesnikoff J, Galli SJ. New developments in mast cell biology. Nat Immunol. 2008;9(11):1215\u0026ndash;22.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGalli SJ, Tsai M, Piliponsky AM. Development of allergic inflammation. Nature. 2008;454:445\u0026ndash;54.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYarovinsky TO, et al. Substance P\u0026ndash;mast cell interactions. J Neuroimmunol. 2013;266:20\u0026ndash;6.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eTheoharides TC, Kavaliotis J, Panagiotou M, et al. Mast cells in neuroinflammatory disorders. Int Rev Neurobiol. 2016;131:25\u0026ndash;44.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRittner HL, Brack A, et al. Mast cell\u0026ndash;nociceptor interactions in pain. Curr Opin Neurobiol. 2013;23:560\u0026ndash;7.\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med. 2010;16:1248\u0026ndash;57.\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"","lastPublishedDoi":"10.21203/rs.3.rs-8202736/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8202736/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eSome patients present with overlapping but unexplained symptoms pelvic pain, fatigue, urticaria, palpitations, gastrointestinal distress, neuropathic pain, and mood dysregulation. These symptoms, traditionally diagnosed under separate labels (endometriosis, MCAS, IBS, dysautonomia, chronic fatigue),We share a unifying pathophysiological signature disruption of neuro-immune-endocrine coordination.\u003c/p\u003e\u003cp\u003eWe define this as \u003cb\u003eNeuro-Immune-Endocrine Integration Failure (NIEIF)\u003c/b\u003e, clinically observed as the \u003cb\u003ePurusharth\u0026ndash;Neha Multisystem Stress-Responsive Dysregulation Syndrome (PN-MSRDS)\u003c/b\u003e. NIEIF represents a systems-level breakdown in communication between mast cells, cytokine networks, neurogenic circuits, and hormonal regulators. This article expands the mechanistic model, clinical spectrum, diagnostic algorithms, and therapeutic rationale for this newly characterized condition.\u003c/p\u003e","manuscriptTitle":"Neuro-Immune-Endocrine Integration Failure (NIEIF)","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-11-26 06:42:38","doi":"10.21203/rs.3.rs-8202736/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"28dfe2f0-596a-47a1-816b-1c851e6ef9de","owner":[],"postedDate":"November 26th, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-12-10T09:10:02+00:00","versionOfRecord":[],"versionCreatedAt":"2025-11-26 06:42:38","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8202736","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8202736","identity":"rs-8202736","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}